TY - JOUR
T1 - Obesity and cancer mechanisms
T2 - Tumor microenvironment and inflammation
AU - Iyengar, Neil M.
AU - Gucalp, Ayca
AU - Dannenberg, Andrew J.
AU - Hudis, Clifford A.
N1 - Funding Information:
Supported by the Breast Cancer Research Foundation, the Botwinick-Wolfensohn Foundation (in memory of Mr. and Mrs. Benjamin Botwinick), and Memorial Sloan Kettering Cancer Center Support Grant/Core Grant No. P30 CA008748.
Publisher Copyright:
© 2016 by American Society of Clinical Oncology.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/12/10
Y1 - 2016/12/10
N2 - Purpose: There is growing evidence that inflammation is a central and reversible mechanism through which obesity promotes cancer risk and progression. Methods: We review recent findings regarding obesity-associated alterations in the microenvironment and the local and systemic mechanisms through which these changes support tumor growth. Results: Locally, hyperadiposity is associated with altered adipose tissue function, adipocyte death, and chronic low-grade inflammation. Most individuals who are obese harbor inflamed adipose tissue, which resembles chronically injured tissue, with immune cell infiltration and remodeling. Within this distinctly altered local environment, several pathophysiologic changes are found that may promote breast and other cancers. Consistently, adipose tissue inflammation is associated with a worse prognosis in patients with breast and tongue cancers. Systemically, the metabolic syndrome, including dyslipidemia and insulin resistance, occurs in the setting of adipose inflammation and operates in concert with local mechanisms to sustain the inflamed microenvironment and promote tumor growth. Importantly, adipose inflammation and its protumor consequences can be found in some individuals who are not considered to be obese or overweight by body mass index. Conclusion: The tumor-promoting effects of obesity occur at the local level via adipose inflammation and associated alterations in the microenvironment, as well as systemically via circulating metabolic and inflammatory mediators associated with adipose inflammation. Accurately characterizing the obese state and identifying patients at increased risk for cancer development and progression will likely require more precise assessments than body mass index alone. Biomarkers of adipose tissue inflammation would help to identify high-risk populations. Moreover, adipose inflammation is a reversible process and represents a novel therapeutic target that warrants further study to break the obesity-cancer link.
AB - Purpose: There is growing evidence that inflammation is a central and reversible mechanism through which obesity promotes cancer risk and progression. Methods: We review recent findings regarding obesity-associated alterations in the microenvironment and the local and systemic mechanisms through which these changes support tumor growth. Results: Locally, hyperadiposity is associated with altered adipose tissue function, adipocyte death, and chronic low-grade inflammation. Most individuals who are obese harbor inflamed adipose tissue, which resembles chronically injured tissue, with immune cell infiltration and remodeling. Within this distinctly altered local environment, several pathophysiologic changes are found that may promote breast and other cancers. Consistently, adipose tissue inflammation is associated with a worse prognosis in patients with breast and tongue cancers. Systemically, the metabolic syndrome, including dyslipidemia and insulin resistance, occurs in the setting of adipose inflammation and operates in concert with local mechanisms to sustain the inflamed microenvironment and promote tumor growth. Importantly, adipose inflammation and its protumor consequences can be found in some individuals who are not considered to be obese or overweight by body mass index. Conclusion: The tumor-promoting effects of obesity occur at the local level via adipose inflammation and associated alterations in the microenvironment, as well as systemically via circulating metabolic and inflammatory mediators associated with adipose inflammation. Accurately characterizing the obese state and identifying patients at increased risk for cancer development and progression will likely require more precise assessments than body mass index alone. Biomarkers of adipose tissue inflammation would help to identify high-risk populations. Moreover, adipose inflammation is a reversible process and represents a novel therapeutic target that warrants further study to break the obesity-cancer link.
UR - http://www.scopus.com/inward/record.url?scp=85002854064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002854064&partnerID=8YFLogxK
U2 - 10.1200/JCO.2016.67.4283
DO - 10.1200/JCO.2016.67.4283
M3 - Article
C2 - 27903155
AN - SCOPUS:85002854064
VL - 34
SP - 4270
EP - 4276
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 35
ER -